HAT Activator Compounds for Neurodegenerative Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cognitive neurodegenerative disorders, such as Alzheimer's disease, lack effective methods to address synaptic dysfunction and amyloid-beta peptide accumulation, with existing histone acetyltransferase (HAT) activators having poor solubility and membrane permeability, limiting their therapeutic potential.
Innovation Solution
Development of compounds with histone acetyltransferase activity, high selectivity, and blood-brain-barrier permeability, such as those represented by Formulae (I), (II), (III), and (IV), which can modulate histone acetylation and penetrate the blood-brain barrier, thereby treating conditions associated with amyloid-beta peptide deposits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing HAT activators are used to treat Alzheimer's disease, then histone acetylation is modulated, but solubility and membrane permeability are poor
Solution Approach 1:
The patent modifies the chemical parameters of HAT activator compounds by introducing specific substituents (halogen atoms, trifluoromethyl groups, ether linkages) and optimizing molecular weight and polar surface area to achieve both therapeutic effectiveness and improved solubility/membrane permeability properties
Solution Approach 2:
The patent creates composite molecular structures combining aromatic rings, heterocyclic systems, and functional groups in specific configurations to achieve multiple properties simultaneously: HAT activation capability, improved solubility, and enhanced membrane permeability
2Reliability
If HAT activator compounds are administered to treat Alzheimer's disease, then amyloid-beta deposits are reduced, but the compounds must penetrate the blood-brain barrier
Solution Approach 1:
The patent optimizes molecular parameters including molecular weight (500-700 Da), polar surface area (70-120 Ų), and lipophilicity to enable blood-brain barrier penetration while maintaining therapeutic effectiveness against amyloid-beta deposits
Solution Approach 2:
The patent describes compounds that act as intermediaries to facilitate HAT activation specifically in the brain by penetrating the blood-brain barrier, delivering the therapeutic effect to the target site while avoiding systemic side effects
3Reliability
If HAT activators are used to enhance memory and cognition, then synaptic plasticity is improved, but the compounds must have high selectivity for histone acetylation
Solution Approach 1:
The patent describes compounds with specific molecular features (aromatic rings, heterocyclic systems, specific functional groups) that provide localized interaction with HAT enzymes, ensuring selective histone acetylation while avoiding off-target effects on other enzymatic processes
Solution Approach 2:
The patent optimizes the EC50 value to be in the range of 10-1000 nM, ensuring high potency and selectivity for HAT activation, which translates to effective memory enhancement with minimal required dosage and reduced off-target effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively decrease amyloid beta protein deposits and improve memory retention and synaptic plasticity, offering a potential therapeutic approach for neurodegenerative diseases by enhancing histone acetylation across the blood-brain barrier with minimal side effects.
Implementation Method 1
the compound increases histone acetylation. In further embodiments, histone acetylation comprises acetylation of histones H2B, H3, H4
Data Source
Figure 1~2
Figure 3~5
Figure 6~7
AI summary
The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.